J
Jessie Villanueva
Researcher at Wistar Institute
Publications - 46
Citations - 4443
Jessie Villanueva is an academic researcher from Wistar Institute. The author has contributed to research in topics: Melanoma & MAPK/ERK pathway. The author has an hindex of 20, co-authored 43 publications receiving 3869 citations. Previous affiliations of Jessie Villanueva include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva,Adina Vultur,John T. Lee,Rajasekharan Somasundaram,Mizuho Fukunaga-Kalabis,Angela K. Cipolla,Bradley Wubbenhorst,Xiaowei Xu,Phyllis A. Gimotty,Damien Kee,Ademi Santiago-Walker,Richard Letrero,Kurt D'Andrea,Anitha Pushparajan,James Hayden,Kimberly Dahlman Brown,Sylvie Laquerre,Grant A. McArthur,Jeffrey A. Sosman,Katherine L. Nathanson,Meenhard Herlyn +20 more
TL;DR: Increased IGF-1R and pAKT levels in a post-relapse human tumor sample are consistent with a role for IGF- 1R/PI3K-dependent survival in the development of resistance to BRAF inhibitors.
Journal ArticleDOI
Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
Alexander Roesch,Adina Vultur,Ivan Bogeski,Huan Wang,Katharina M. Zimmermann,David W. Speicher,Christina Körbel,Matthias W. Laschke,Phyllis A. Gimotty,Stephan E. Philipp,Elmar Krause,Sylvie Pätzold,Jessie Villanueva,Clemens Krepler,Mizuho Fukunaga-Kalabis,Markus Hoth,Boris C. Bastian,Thomas Vogt,Meenhard Herlyn +18 more
TL;DR: These findings support a two-tiered approach combining anticancer agents that eliminate rapidly proliferating melanoma cells with inhibitors of the drug-resistant slow-cycling subpopulation, and support an intrinsic multidrug resistance based on the survival of a tumor cell subpopulation.
Journal ArticleDOI
Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma
Xiao Hong Ma,Sheng Fu Piao,Souvik Dey,Quentin McAfee,Giorgos C. Karakousis,Jessie Villanueva,Lori S. Hart,Samuel M. Levi,Janice Hu,Gao Zhang,Rossitza Lazova,Vincent Klump,John M. Pawelek,Xiaowei Xu,Wei Xu,Lynn M. Schuchter,Michael A. Davies,Meenhard Herlyn,Jeffrey D. Winkler,Constantinos Koumenis,Ravi K. Amaravadi +20 more
TL;DR: Using tumor biopsies from BRAF(V600E) melanoma patients treated either with BRAFi or with combined BRAF and MEK inhibition, it is found that BRAFi-resistant tumors had increased levels of autophagy compared with baseline and a rationale for combination approaches targeting this resistance pathway is provided.
Journal ArticleDOI
Timing of cyclin D1 expression within G1 phase is controlled by Rho
Catherine F. Welsh,Kristin Roovers,Jessie Villanueva,Yun Qi Liu,Martin A. Schwartz,Richard K. Assoian +5 more
TL;DR: The results show that Rho is crucial for maintaining the correct timing of cyclin D1 expression in G1 phase and describe a new role for cytoskeletal integrity in the regulation of cell cycle progression.
Journal ArticleDOI
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
Keiran S.M. Smalley,Min Xiao,Jessie Villanueva,Thierry-Thien K. Nguyen,Keith T. Flaherty,Richard Letrero,P. Van Belle,David E. Elder,Yue J. Wang,Katherine L. Nathanson,Meenhard Herlyn +10 more
TL;DR: A group of melanomas with low-activity BRAF mutations that are reliant upon CRAF-mediated survival activity are identified and sorafenib was more potent at reducing the growth of tumors with the D594G mutation than those with the V600E mutation.